20132020
If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2013 2020

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function

Van Der Steen, N., Keller, K., Dekker, H., Porcelli, L., Honeywell, R. J., Van Meerloo, J., Musters, R. J. P., Kathmann, I., Frampton, A. E., Liu, D. S. K., Ruijtenbeek, R., Rolfo, C., Pauwels, P., Giovannetti, E. & Peters, G. J., 1 Jan 2020, In : Journal of Cellular Physiology.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., Boellaard, R., van Herpen, C. M. L., de Vries, E. G. E., Oyen, W. J. G., Brouwers, A. H., Verheul, H. M. W., Hoekstra, O. S. & Menke-van der Houven van Oordt, C. W., 2019, In : European Journal of Nuclear Medicine and Molecular Imaging.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line

van der Steen, N., Leonetti, A., Keller, K., Dekker, H., Funel, N., Lardon, F., Ruijtenbeek, R., Tiseo, M., Rolfo, C., Pauwels, P., Peters, G. J. & Giovannetti, E., 2019, In : Biochemical Pharmacology. 166, p. 128-138

Research output: Contribution to journalArticleAcademicpeer-review

Enhanced Dendritic Cell Development Through Long-Term Proteasome Inhibition

van de Ven, R., Verbrugge, S. E., Al, M., Dekker, H., Verheul, HMW., Anderl, J. L., Chan, E. T., Dijkmans, BAC., Lems, WF., Scheper, RJ., Jansen, G. & de Gruijl, TD., 18 Jan 2018, In : Journal of Molecular and Clinical Medicine. 1, 1, p. 37-46 10 p., DOI: 10.31083/j.jmcm.2018.01.005.

Research output: Contribution to journalArticleAcademicpeer-review

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab

Walraven, M., Homs, M. Y. V., van der Veldt, A. A. M., Dekker, H., Koldenhof, J., Honeywell, R., Barendrecht, A., Sebastian, S. A. E., Parr, N., Koekman, A. C., Voest, E. E., Roest, M., Korporaal, S. J. A. & Verheul, H. M. W., 2018, In : Angiogenesis. 21, 2, p. 325-334

Research output: Contribution to journalArticleAcademicpeer-review

Open Access